Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab

Leukemia and Lymphoma

Volumn 49, Issue 10, 2008, Pages 2018-2021

  Liu, Chun Yu ^a,b   Teng, Hao Wei ^a,b   Lirng, Jiing Feng ^b   Chiou, Tzeon Jye ^a,b   Chen, Po Min ^a,b   Hsiao, Liang Tsai ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; EPIRUBICIN; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; AGED; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DYSARTHRIA; DYSPHAGIA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERSALIVATION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; REMISSION INDUCTION;

EID: 55049116646     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802311375     Document Type: Conference Paper

References (15)

1. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. Bouabdallah, R. et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 235-242.
2. Feugier, P., Virion, J. M., Tilly, H., Haioun, C., Marit, G. Macro, M. et al. (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol, 15, pp. 129-133.
3. Hollender, A., Kvaloy, S., Lote, K., Nome, O. and Holte, H. (2000) Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer, 36, pp. 1762-1768.
4. Jahnke, K., Thiel, E., Martus, P., Schwartz, S. and Korfel, A. (2006) Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol, 85, pp. 45-50.
5. Bokstein, F., Lossos, A., Lossos, I. S. and Siegal, T. (2002) Central nervous system relapse of systemic non-Hodgkin's lymphoma: Results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma, 43, pp. 587-593.
6. Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard, J. E. Raab, R. et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, pp. 435-445.
7. Rubenstein, J. L., Combs, D., Rosenberg, J., Levy, A., McDermott, M. Damon, L. et al. (2003) Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. Blood, 101, pp. 466-468.
8. Pels, H., Schulz, H., Manzke, O., Hom, E., Thall, A. Engert, A. et al. (2002) Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol, 59, pp. 213-216.
9. Pels, H., Schulz, H., Schlegel, U. and Engert, A. (2003) Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: Experience with two cases and review of the literature. Onkologie, 26, pp. 351-354.
10. Schulz, H., Pels, H., Schmidt-Wolf, I., Zeelen, U., Germing, U. Engert, A. et al. (2004) Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica, 89, pp. 753-754.
11. Antonini, G., Cox, M. C., Montefusco, E., Ferrari, A., Conte, E. Morino, S. et al. (2007) Intrathecal anti-CD20 antibody: An effective and safe treatment for leptomeningeal lymphoma. J Neurooncol, 81, pp. 197-199.
12. Rubenstein, J. L., Fridlyand, J., Abrey, L., Shen, A., Karch, J. Wang, E. et al. (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol, 25, pp. 1350-1356.
13. Bjorkholm, M., Hagberg, H., Holte, H., Kvaloy, S., Teerenhovi, L. Anderson, H. et al. (2007) Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol, 18, pp. 1085-1089.
14. Plotkin, S. R., Betensky, R. A., Hochberg, F. H., Grossman, S. A., Lesser, G. J. Nabors, L. B. et al. (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res, 10, pp. 5643-5646.
15. Boehme, V., Zeynalova, S., Kloess, M., Loeffler, M., Kaiser, U. Pfreundschuh, M. et al. (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol, 18, pp. 149-157.